- Home
- ANAB vs VMEO Comparison
ANAB vs VMEO Comparison
Compare ANAB & VMEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- VMEO
- Stock Information
- Founded
- ANAB 2005
- VMEO 2004
- Country
- ANAB United States
- VMEO United States
- Employees
- ANAB N/A
- VMEO N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- VMEO Computer Software: Prepackaged Software
- Sector
- ANAB Health Care
- VMEO Technology
- Exchange
- ANAB Nasdaq
- VMEO Nasdaq
- Market Cap
- ANAB 759.5M
- VMEO 751.2M
- IPO Year
- ANAB 2017
- VMEO N/A
- Fundamental
- Price
- ANAB $22.23
- VMEO $4.37
- Analyst Decision
- ANAB Buy
- VMEO Buy
- Analyst Count
- ANAB 10
- VMEO 4
- Target Price
- ANAB $42.25
- VMEO $7.35
- AVG Volume (30 Days)
- ANAB 559.5K
- VMEO 1.3M
- Earning Date
- ANAB 05-05-2025
- VMEO 05-05-2025
- Dividend Yield
- ANAB N/A
- VMEO N/A
- EPS Growth
- ANAB N/A
- VMEO N/A
- EPS
- ANAB N/A
- VMEO 0.10
- Revenue
- ANAB $111,872,000.00
- VMEO $415,130,000.00
- Revenue This Year
- ANAB N/A
- VMEO $3.90
- Revenue Next Year
- ANAB $9.72
- VMEO $6.17
- P/E Ratio
- ANAB N/A
- VMEO $42.77
- Revenue Growth
- ANAB 387.20
- VMEO N/A
- 52 Week Low
- ANAB $12.21
- VMEO $3.45
- 52 Week High
- ANAB $41.31
- VMEO $7.90
- Technical
- Relative Strength Index (RSI)
- ANAB 62.32
- VMEO 34.23
- Support Level
- ANAB $20.50
- VMEO $4.35
- Resistance Level
- ANAB $22.84
- VMEO $4.52
- Average True Range (ATR)
- ANAB 1.28
- VMEO 0.11
- MACD
- ANAB 0.12
- VMEO -0.02
- Stochastic Oscillator
- ANAB 83.24
- VMEO 3.57
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.